Please assess the completion status of the following clinical trial:

Trial Title: Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with functional dyspepsia or peptic ulcers~* Subjects between the ages of 19 and 70 years old~* Subjects who were referred for upper endoscopy, and had not received previous H. pylori eradication treatment within the last six months.~* Subjects who had not received anti-secreting acid, bismuth or antibiotics for other diseases 15 days before the endoscopy.~* For the study, only patients with sensitive isolates of H.pylori to amoxicillin and clarithromycin were included.~Exclusion Criteria:~* Patients with serious comorbidities.~* Pregnant women.~* Patients allergic to the medications used in this study.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- amoxicillin clarithromycin omeprazole 1 (Type: EXPERIMENTAL): This group received triple standard therapy with standard doses of omeprazole. 20 mg omeprazole before breakfast and before dinner. 500 mg clarithromycin after breakfast and after dinner and 1 g amoxicillin after breakfast and after dinner for 10 days.
- amoxicillin clarithromycin omeprazole 2 (Type: EXPERIMENTAL): This group received triple standard therapy, using 500 mg clarithromycin after breakfast and after dinner and 1 g amoxicillin after breakfast and after dinner for 10 days in addition with omeprazole but omeprazole doses were prescribed according to CYP2C19 genotype as a follows: a) Patients with CYP2C19 \*1/\*1 genotype (Early and ultrarapid Metabolizer): 40mg omeprazole before breakfast and before dinner. b) Patients with CYP2C19 \*1/\*2 or \*1/\*3 genotype (Intermediate Metabolizer): 20mg omeprazole before breakfast, 20mg before lunch and 20mg before dinner. c) Patients with CYP2C19 \*2/\*2 (Poor Metabolizer): 20mg omeprazole before breakfast and 20 mg before dinner.

Based on this trial design, predict the completion outcome and termination type (if applicable).